Want to join the conversation?
$ESRX's cost of pharmacy benefit management revenue for 2015 rose by $129.6MM from last year. This increase is primarily due to inflation on branded drugs, partially offset by lower claims volume, better management of ingredient costs and impact of increased aggregate generic fill rate, which grew to 84.4% in 2015 from 82.9% in 2014.
$MON shares dip slightly; I wonder this is because of the environmental lawsuit filed by the Washington state against the production of PCBs.
My bet is that $FR will reach $32 in the short term. It’s time it broke the 52-week high and had its fair share of growth.
$WYNN got bruised up by China after its decision to cut withdrawal limit in Macau ATMs. Wynn Resorts shares went down by more than 11%! Well who could have guessed that right?